At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 133 enrolled
Drug / intervention
IMM-124E +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis.
In Brief
A Phase 2 clinical trial evaluating IMM-124E and Placebo for Non-alcoholic Steatohepatitis (NASH). Completed, enrolled 133 participants across 25 sites in 3 countries.
Detailed Summary
This study will evaluate the safety and preliminary efficacy of two dose levels of IMM-124E in reducing liver fat and/or serum alanine aminotransaminase (ALT) compared with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Steatohepatitis (NASH)
CountriesAustralia, Israel, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedDec 2014
Primary CompletionOct 2017
TodayJul 2026
First PostedDec 15, 2014
Enrollment StartDec 1, 2014
Primary CompletionOct 30, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 11.5 years ago
Interventions
IMM-124Ebiological
IMM-124E
Placeboother
Matched placebo